Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs

Hypertension Research

Volumn 35, Issue 3, 2012, Pages 245-250

  Ueno, Koichi ^a   Sato, Hiromi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

anti hypertensive drug; pharmacodynamics; pharmacokinetics; sex differences

Indexed keywords

ALPHA HYDROXYMETOPROLOL; AMLODIPINE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; CARVEDILOL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGOXIN; DIPHENHYDRAMINE; ENALAPRIL; ENALAPRILAT; ERYTHROMYCIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GLYCOPROTEIN P; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; LISINOPRIL; METOPROLOL; NORVERAPAMIL; PROPRANOLOL; TESTOSTERONE; TORASEMIDE; VALSARTAN; VERAPAMIL;

ANGINA PECTORIS; CLEARANCE; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; GENETIC POLYMORPHISM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; URINARY EXCRETION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; SEX CHARACTERISTICS;

EID: 84857925482     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.189     Document Type: Review

References (50)

1. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol 2008; 83: 1-10.
2. Schwartz JB. Drug metabolism. In Legato MJ (eds) Principles of Gender-Specific Medicine 2nd edn, Elsevier Academic Press: San Diego 2004, pp 825-829.
3. Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. Workshop held at the National Institute of Health, May 4-6, 1999. J Womens Health Gend Based Med 2002; 11: 601-615.
4. Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos 2006; 27: 329-334. (Pubitemid 44687786)
5. Wolbold R, Klein K, Burk O, Nü ssler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38: 978-988. (Pubitemid 37221681)
6. George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995; 50: 727-730.
7. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, Kremers P. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48: 365-374. (Pubitemid 20362269)
8. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423. (Pubitemid 24229655)
9. Cummins CL, Wu C-Y, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474-489. (Pubitemid 36237718)
10. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther 2000; 68: 286-292.
11. Krecic-Shepard ME, Barnas CR, Slimko J, Groski J, WainerI, Schwartz JB. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 1999; 66: 40-50. (Pubitemid 29350444)
12. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M. and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol 1996; 77: 713-722.
13. de Bruijn B, Cocco G, Tyler HM. Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S107-S109. (Pubitemid 19014200)
14. Lorimer AR, Smedsrud T, Walker P, Tyler HM. Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 1988; (Suppl 7): S89-S93. (Pubitemid 19014196)
15. Kang D, Verotta D, Schwartz JB. Population analyses of amlodipine in patients living in the community and patients living in nursing homes. Clin Pharmacol Ther 2006; 79: 114-124. (Pubitemid 43069583)
16. Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004; 76: 467-479. (Pubitemid 39469870)
17. Tatchum-Talom R, Eyster KM, Martin DS. Sexual dimorphism in angiotensin II-induced hypertension and vascular alterations. Can J Physiol Pharmacol 2005; 83: 413-422. (Pubitemid 41003316)
18. Xue B, Pamidimukkala J, Hay M. Sex differences in the development of angiotensin IIinduced hypertension in conscious mice. Am J Physiol Heart Circ Physiol 2005; 288: H2177-H2184. (Pubitemid 40604103)
19. Ellison KE, Ingelfinger JR, Pivor M, Dzau VJ. Androgen regulation of rat renal angiotensinogen messenger RNA expression. J Clin Invest 1989; 83: 1941-1945. (Pubitemid 19148864)
20. Sartori-Valinotti JC, Iliescu R, Yanes LL, Dorsett-Martin W, Reckelhoff JF. Sex differences in the pressor response to angiotensin II when the endogenous renin-angiotensin system is blocked. Hypertension 2008; 51: 1170-1176. (Pubitemid 351398978)
21. Xue B, Pamidimukkala J, Lubahn DB, Hay M. Estrogen receptor-alpha mediates estrogen protection from angiotensin II-induce hypertension in conscious female mice. Am J Physiol Heart Circ Physiol 2007; 292: H1770-H1776. (Pubitemid 46572400)
22. Saruta T. The contribution of ARB to medical treatment. Nippon Rinsho 2009; 67: 662-667.
23. Suzuki H, Araki R. Cardiovascular outcome of an angiotensin II receptor blocker, candesartan, in Japan. Drugs Today (Barc) 2010; 46: 427-431.
24. Saunders E, Cable G, Neutel J. Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study. J Clin Hypertens (Greenwich) 2008; 10: 27-33.
25. McBride SM, Flynn FW, Ren J. Cardiovascular alteration and treatment of hypertension: do men and women differ? Endocrine 2005; 28: 199-207. (Pubitemid 43037681)
26. Bristol-Myers Squibb. AVAPRO and AVALIDE: Hypertension treatment. Full Prescribing Information for AVALIDEs (irbesartan-hydrochlorothiazide). http://packageinserts.bms. com/pi/pi-avalide.pdf (accessed 2 May 2011).
27. Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR, Zimpelmann J, Gao W, Cattran DC, Scholey JW. Gender differences in the renal response to reninangiotensin system blockade. J Am Soc Nephrol 2006; 17: 2554-2560. (Pubitemid 44300971)
28. Everett BM, Glynn RJ, Danielson E, Ridker PM. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther 2008; 30: 661-672. (Pubitemid 351680499)
29. Zapater P, Novalbos J, Gallego-Sandín S, Hernández FT, Abad-Santos F. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. J Cardiovasc Pharmacol 2004; 43: 737-744. (Pubitemid 38534076)
30. lconnet C, Bochud M, Bovet P, Maillard M, Burnier M. Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent. J Hypertens 2004; 22: 1213-1220. (Pubitemid 38721013)
31. Sullivan JC. Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1220-R1226. (Pubitemid 351490641)
32. Pretorius M, Luther JM, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arterioscler Thromb Vasc Biol 2005; 25: 2435-2440. (Pubitemid 41552667)
33. Werner D, Werner U, Meybaum A, Schmidt B, Umbreen S, Grosch A, Lestin HG, Graf B, Zolk O, Fromm MF. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet 2008; 47: 323-332. (Pubitemid 351508118)
34. Cerrutti JA, Quaglia NB, Brandoni A, Torres AM. Effects of gender on the pharmacokinetics of drugs secreted by the renal organic anions transport systems in the rat. Pharmacol Res 2002; 45: 107-112. (Pubitemid 35428844)
35. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42: 107-121. (Pubitemid 36188552)
36. Fletcher A, Beevers DG, Bulpitt C, Butler A, Coles EC, Hunt D, Munro-Faure AD, Newson RB, O'Riordan PW, Petrie JC. Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens 1988; 2: 219-227. (Pubitemid 19028278)
37. b-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-1714.
38. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999; 66: 594-601. (Pubitemid 30014086)
39. Cocco G, Chu D. The anti-ischemic effect of metoprolol in patients with chronic angina pectoris is gender-specific. Cardiology 2006; 106: 147-153. (Pubitemid 44474982)
40. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 1983; 34: 732-737. (Pubitemid 14219918)
41. Hamelin BA, Bouayad A, Méthot J, Jobin J, Desgagnés P, Poirier P, Allaire J, Dumesnil J, Turgeon J. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 2000; 67: 466-477. (Pubitemid 30327485)
42. Sharma A, Pibarot P, Pilote S, Dumesnil JG, Arsenault M, Bélanger PM, Meibohm B, Hamelin BA. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J Pharmacol Exp Ther 2005; 313: 1172-1181. (Pubitemid 40727020)
43. Sharma A, Pibarot P, Pilote S, Dumesnil JG, Arsenault M, Bélanger PM, Meibohm B, Hamelin BA. Toward optimal treatment in women: the effect of sex on metoprololdiphenhydramine interaction. J Clin Pharmacol 2010; 50: 214-225.
44. Xie HG, Chen X. Sex differences in pharmacokinetics of oral propranolol in healthy Chinese volunteers. Zhongguo Yao Li Xue Bao 1995; 16: 468-470.
45. Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989; 46: 257-263. (Pubitemid 19254757)
46. Walle T, Walle K, Mathur RS, Palesch YY, Conradi EC. Propranolol metabolism in normal subjects: association with sex steroid hormones. Clin Pharmacol Ther 1994; 56: 127-132. (Pubitemid 24274178)
47. Baris N, Kalkan S, Güneri S, Bozdemir V, Guven H. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? Eur J Clin Pharmacol 2006; 62: 535-538.
48. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41: 329-342. (Pubitemid 34713088)
49. Aiba T, Ishida K, Yoshinaga M, Okuno M, Hashimoto Y. Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. Biol Pharm Bull 2005; 28: 114-119. (Pubitemid 40879794)
50. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K. Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci 2002; 70: 1491-1500. (Pubitemid 34164543)